New report predicts growth of gene therapies for neurology indications
A new report has predicted that gene therapy development will pick up pace but a high price point continues to pose a challenge.
List view / Grid view
A new report has predicted that gene therapy development will pick up pace but a high price point continues to pose a challenge.
A new agreement will allow eligible cystic fibrosis patients in England to have access to CFTR modulators to treat the underlying cause of their disease.
The FDA has released an additional NDMA testing method and has alerted the public to multiple voluntary recalls of ranitidine.
Speaker Pelosi’s bill to lower medicine prices in the US has passed through a House committee, ready for a full vote.
Farxiga, a treatment to reduce the risk of heart failure in patients with type 2 diabetes has been approved by the FDA.
Aducanumab, an Alzheimer's disease treatment, will be submitted as part of a Biologics License Application after meeting clinical trial primary endpoints.
Teva has agreed to supply opioid medication and make a cash payment in a settlement agreement that removes it from the Track 1 opioid litigation.
Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of HER2-positive metastatic breast cancer.
The fight against antibiotic resistance could be improved with the discovery of a concept for fabricating nanomeshes as a drug delivery system.
The EMA CHMP has given a positive opinion for marketing authorisation approval to seven medicines following its October meeting.
A new report has said the osteoarthritis therapeutics market is estimated to grow due to rapid increase in the geriatric and obese population.
A new report has shown that from 2016/17 to 2018/19 clinical research has generated an estimated £8 billion of GVA for the UK.
Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
Why has the pharma industry and its talents lost interest in developing new antibiotics?